Basel, October 5, 2006 -- Exciting new clinical data demonstrate that 90 to 95 percent of treatment-experienced HIV patients who initiate therapy with FUZEON (enfuvirtide) and the investigational integrase inhibitor MK-0518 can achieve undetectable levels of HIV (less than 400 copies per mL of blood)1. Such response rates have never been achieved in clinical trials of HIV patients living with drug-resistant virus. This significant antiviral effect achieved by adding FUZEON to other new drugs, known as the "FUZEON effect", has been consistently demonstrated across a number of studies.2 These data were presented at the 46th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
"These remarkable results show us that by partnering FUZEON and a novel integrase inhibitor, treatment-experienced patients can have a similar chance to achieve the ultimate goal of treatment, undetectable viral load, as treatment-nave patients," said Dr Anton Pozniak, the Chelsea and Westminster Hospital, London. "Today, we already see that using FUZEON with darunavir or tipranavir, we have the right drugs to help us achieve the treatment goal of undetectable viral load in the majority of treatment-experienced patients. But more importantly we look set to achieve this goal of undetectable in more patients in the future with the availability of FUZEON and exciting novel agents such as MK-0518."
About the results presented at ICAAC
Investigators reported results of a 24-week, Phase II, Merck-sponsored study of MK-0518 in treatment-experienced patients with resistance to protease inhibitors, nucleoside analogues and non-nucleoside analogues. Patients received one of three doses of MK-0518 (200 mg, 400 mg or 600 mg) twice-daily in combination with an optimised background regimen of anti-HIV drugs. In the subset of patients who received FUZEON for the first time in their drug regimen, 90 to 95 percent of 32 subjects achieved undetec
Contact: Alexander Watson